Association of serum fetuin A with truncal obesity and dyslipidemia in non-diabetic hemodialysis patients

European Journal of Endocrinology

Volumn 160, Issue 5, 2009, Pages 777-783

  Chen, Hung Yuan ^a,b   Chiu, Yen Lin ^a,b   Hsu, Shih Ping ^a,b   Pai, Mei Fen ^a,b   Lai, Chun Fu ^a,b   Peng, Yu Sen ^a,b   Kao, Tze Wah ^b   Hung, Kuan Yu ^b   Tsai, Tun Jun ^b   Wu, Kwan Dun ^b  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CREATINE; FETUIN A; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ALPHA2HS GLYCOPROTEIN; LIPOPROTEIN; PLASMA PROTEIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; IRON BINDING CAPACITY; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ABDOMEN; BLOOD; INCIDENCE; KIDNEY FAILURE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; STATISTICS; THORAX;

ABDOMEN; AGED; BLOOD PROTEINS; DYSLIPIDEMIAS; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE; LIPOPROTEINS; MALE; MIDDLE AGED; OBESITY; RENAL DIALYSIS; THORAX; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 65549101411     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0813     Document Type: Article

References (31)

1. Kalabay L, Chavin K, Lebreton JP, Robinson KA, Buse MG & Arnaud P. Human recombinant alpha 2-HS glycoprotein is produced in insect cells as a full length inhibitor of the insulin receptor tyrosine kinase. Hormone and Metabolic Research 1998 30 1-6.
2. Rauth G, Poschke O, Fink E, Eulitz M, Tippmer S, Kellerer M, Haring HU, Nawratil P, Haasemann M, Jahnen-Dechent W & Muller-Esterl W. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. European Journal of Biochemistry 1992 204 523-529.
3. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT & Dekker FW. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney International 2007 72 202-207.
4. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M & Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006 113 1760-1767.
5. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Krober SM, Machicao F, Fritsche A & Haring HU. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006 29 853-857.
6. Axelsson J, Wang X, Ketteler M, Qureshi AR, Heimburger O, Barany P, Lindholm B, Nordfors L & Stenvinkel P. Is fetuin-A/ alpha2-Heremans-Schmid glycoprotein associated with the metabolic syndrome in patients with chronic kidney disease? American Journal of Nephrology 2008 28 669-676.
7. Tsangalis G, Papaconstantinou S, Kosmadakis G, Valis D & Zerefos N. Prevalence of the metabolic syndrome in hemodialysis. International Journal of Artificial Organs 2007 30 118-123.
8. Yang SY, Chiang CK, Hsu SP, Peng YS, Pai MF, Ho TI, Hung KY & Wu KD. Metabolic syndrome predicts hospitalization in hemodialysis patients: a prospective Asian cohort study. Blood Purification 2007 25 252-259.
9. Balkau B, Deanfield JE, Despres JP, Bassand JP, Fox KA, Smith SC Jr, Barter P, Tan CE, Van Gaal L, Wittchen HU, Massien C & Haffner SM. International day for the evaluation of abdominal obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007 116 1942-1951.
10. Janiszewski PM, Janssen I & Ross R. Does waist circumference predict diabetes and cardiovascular disease beyond commonly evaluated cardiometabolic risk factors? Diabetes Care 2007 12 3105-3109.
11. Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, Wisedopas N, Bunnag P & Puavilai G. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World Journal of Gastroenterology 2007 13 3614-3618.
12. Iacobellis G, Assael F, Ribaudo MC, Zappaterreno A, Alessi G, Di Mario U & Leonetti F. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obesity Research 2003 11 304-310.
13. Vega GL, Adams-Huet B, Peshock R, Willett D, Shah B & Grundy SM. Influence of body fat content and distribution on variation in metabolic risk. Journal of Clinical Endocrinology and Metabolism 2006 91 4459-4466.
14. Chen HY, Kao TW, Huang JW, Tsai TJ & Wu KD. Association between dyslipidemia and residual renal function in patients on chronic peritoneal dialysis. Clinical Nephrology 2008 70 233-239.
15. Chiang CK, Ho TI, Hsu SP, Peng YS, Pai MF, Yang SY, Hung KY & Tsai TJ. Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients. Blood Purification 2005 23 134-140.
16. Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, Chew SK, Chia KS, Tan CE & Tai ES. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006 186 367-373.
17. Cozzolino M, Galassi A, Biondi ML, Turri O, Papagni S, Mongelli N, Civita L, Gallieni M & Brancaccio D. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. American Journal of Nephrology 2006 26 423-429.
18. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W & Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003 361 827-833.
19. Ix JH,Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR & Shlipak MG. Fetuin-A and incident diabetes mellitus in older persons. Journal of the American Medical Association 2008 300 182-188.
20. Lin X, Braymer HD, Bray GA & York DA. Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity. Life Sciences 1998 63 145-153.
21. Vega GL, Chandalia M, Szczepaniak LS & Grundy SM. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007 46 716-722.
22. Kalantar-Zadeh K, Block G, Humphreys MH & Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney International 2003 63 793-808.
23. Dwyer JT, Larive B, Leung J, Rocco MV, Greene T, Burrowes J, Chertow GM, Cockram DB, ChumleaWC, Daugirdas J, Frydrych A & Kusek JW. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? Kidney International 2005 68 1766-1776.
24. Honda H, Qureshi AR, Heimburger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P & Lindholm B. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. American Journal of Kidney Diseases 2006 47 139-148.
25. Enia G, Sicuso C, Alati G & Zoccali C. Subjective global assessment of nutrition in dialysis patients. Nephrology, Dialysis, Transplantation 1993 8 1094-1098.
26. Yoshizumi S, Suzuki S, Hirai M, Hinokio Y, Yamada T, Yamada T, Tsunoda U, Aburatani H, Yamaguchi K, Miyagi T & Oka Y. Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice. Metabolism 2007 56 420-429.
27. Wanner C & Krane V. Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients. American Journal of Kidney Diseases 2003 41 S72-S75.
28. Liu J & Rosner MH. Lipid abnormalities associated with end-stage renal disease. Seminars in Dialysis 2006 19 32-40.
29. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI & Hoff HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 1992 86 475-482.
30. Koda Y, Nishi S, Suzuki M & Hirasawa Y. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney International 1999 71 S251-S253.
31. Prichard SS. Impact of dyslipidemia in end-stage renal disease. Journal of the American Society of Nephrology 2003 14 S315-S320.